Email: yincq@szbl.ac.cn
My research focuses on the regulation of signal transduction pathways mediated by protein post-translational modifications in malignant tumors such as melanoma, with an emphasis on exploring the mechanical role of signal transduction in driving the initiation and development of cancer, the discovery of new drug targets and the development of novel small molecule inhibitors.
To explore intervention opportunities for prevention and treatment of melanoma, I have conducted in-depth research on the initiation and development of melanoma in recent years, and have achieved a series of research accomplishments with important academic value and clinical translational potential. So far, I have published a total of 19 professional academic papers in research fields of signal transduction and melanoma biology, of which 6 were published as the first (including co-first) author in internationally renowned journals such as Cell, Nature, and Nature Communications.
We explained the molecular mechanism of the G protein-coupled receptor MC1R being palmitoylated to suppress the occurrence of melanoma, and developed a pharmaceutical method to prevent the occurrence of melanoma (Nature, 2017). We also revealed serine/threonine kinase STK19 promotes the molecular mechanism of melanoma development through phosphorylation of NRAS, and developed a novel specific small molecule inhibitor that significantly inhibits the development of melanoma (Cell, 2019). I have applied for one U.S. patent and obtained two Chinese patent authorizations. Based on my previous research, I have won the Bristol-Myers Squibb Oncology Scholar-in-Training Award issued by the American Association for Cancer Research (AACR) in 2016, and received a research funding from the National Institutes of Health (NIH) as the sole principal investigator (PI) in 2020 as the K99/R00 NIH Pathway to Independence Award.
Yin, C*; Zhu, B*; Zhang, T*; Liu, T*; Chen, S; Liu, Y; Li, X; Miao, X; Li, S; et al. Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven melanomagenesis. Cell, 2019 Feb 21; 176(5):1113-1127.
Chen, S*; Zhu, B*; Yin, C*; Liu, W; Han, C; Chen, B; Liu, T; Li, X; Chen, X; Li, C; et al. Palmitoylation-dependent activation of MC1R prevents melanomagenesis. Nature, 2017 Sep 21; 549(7672):399-403. (*Co-first author)
Zhu, B*; Chen, S*; Wang, H*; Yin, C*; Han, C*; Peng, C; Liu, Z; Wan, L; et al. The protective role of DOT1L in UV-induced melanomagenesis. Nature Communications, 2018 Jan 17; 9(1):259. (*Co-first author)
Zhu, B*; Tang, L*; Chen, S*; Yin, C*; Peng, S; Li, X; Liu, T; Liu, W; Han, C; et al. Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy.Oncogene, 2018 Sep; 37(36):4941-4954. (*Co-first author)
Chen, S; Han, C; Miao, X; Li, X; Yin, C; Zou, J; Liu, M; Li, S; Stawski, L; Zhu, B; et al. Targeting MC1R depalmitoylation to prevent melanomagenesis in redheads. Nature Communications, 2019 Feb 20; 10(1):877.
